Louis Kohl, MD
Interventional Cardiology · Minneapolis, MNNPI 1023284288
Payments from drug & device makers
What this record shows
This record is dominated by travel and lodging: $1,167 of the $1,853 with a category attached, or 63.0%. Edwards Lifesciences accounts for 77.8% of it on its own, with 4 other manufacturers making up the rest. Reporting peaked in 2019 at $1,442 and has fallen 86.5% since, to $194 in 2025. That places this record below the midpoint for interventional cardiology clinicians in MN, where the typical reported total is $5,396.
Across 24 payments — averaging $77.21 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Edwards Lifesciences$1K
- Abbott$180
- Angiodynamics, Inc.$159
- Shockwave Medical, Inc$58
- Abiomed$14
Across 20 payments — averaging $2331.70 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- CSL Behring$47K
What the payments were for
- Travel & lodging$1,16763%
- Food & beverage$68637%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Edwards Lifesciences | 19 | $1,442 |
| Abbott | 1 | $180 |
| Angiodynamics, Inc. | 1 | $159 |
| Shockwave Medical, Inc | 2 | $58 |
| Abiomed | 1 | $14 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$1,853 in reported general payments places this provider in the 25th percentile of 84 interventional cardiology providers in Minnesota.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| EliquisApixaban | 12 | $11,823 |
| Carvedilol | 53 | $524 |
| Metoprolol Succinate | 20 | $352 |
| Lisinopril | 40 | $283 |
| Atorvastatin Calcium | 36 | $281 |
| Amlodipine Besylate | 17 | $101 |
Paid to pharmacies, not to this prescriber.
Other interventional cardiology in Minneapolis
- Emmanouil BrilakisMinneapolis$548K
- Wesley PedersenMinneapolis$493K
- Michael ManolesMinneapolis$201K
- Jay TraverseMinneapolis$198K
- Robert WilsonMinneapolis$176K
- Yale WangMinneapolis$168K
- Steven RohMinneapolis$67K
- Stefan BertogMinneapolis$64K
- Konstantinos VoudrisMinneapolis$46K
- Michael MooneyMinneapolis$25K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.